Literature DB >> 11685270

Variation in susceptibility to benznidazole in isolates derived from Trypanosoma cruzi parental strains.

V M Veloso1, C M Carneiro, M J Toledo, M Lana, E Chiari, W L Tafuri, M T Bahia.   

Abstract

In this work, the susceptibility to benznidazole of two parental Trypanosoma cruzi strains, Colombian and Berenice-78, was compared to isolates obtained from dogs infected with these strains for several years. In order to evaluate the susceptibility to benznidazole two groups of mice were infected with one of five distinct populations isolated from dogs as well as the two parental strains of T. cruzi. The first group was treated with benznidazole during the acute phase and the second remained untreated controls. The animals were considered cured when parasitological and serological tests remained persistently negative. Mice infected with the Colombian strain and its isolates Colombian (A and B) did not cure after treatment. On the other hand, all animals infected with Berenice-78 were cured by benznidazole treatment. However, 100%, 50% and 70% of cure rates were observed in animals infected with the isolates Berenice-78 B, C and D, respectively. No significant differences were observed in serological profile of infected control groups, with all animals presenting high antibody levels. However, the ELISA test showed differences in serological patterns between mice inoculated with the different T. cruzi isolates and treated with benznidazole. This variability was dependent on the T. cruzi population used and seemed to be associated with the level of resistance to benznidazole.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11685270     DOI: 10.1590/s0074-02762001000700021

Source DB:  PubMed          Journal:  Mem Inst Oswaldo Cruz        ISSN: 0074-0276            Impact factor:   2.743


  9 in total

1.  Transcriptomic signatures of alterations in a myoblast cell line infected with four distinct strains of Trypanosoma cruzi.

Authors:  Daniel Adesse; Dumitru A Iacobas; Sanda Iacobas; Luciana R Garzoni; Maria de Nazareth Meirelles; Herbert B Tanowitz; David C Spray
Journal:  Am J Trop Med Hyg       Date:  2010-05       Impact factor: 2.345

2.  Amiodarone inhibits Trypanosoma cruzi infection and promotes cardiac cell recovery with gap junction and cytoskeleton reassembly in vitro.

Authors:  Daniel Adesse; Eduardo Meirelles Azzam; Maria de Nazareth L Meirelles; Julio A Urbina; Luciana R Garzoni
Journal:  Antimicrob Agents Chemother       Date:  2010-11-15       Impact factor: 5.191

3.  Geographical clustering of Trypanosoma cruzi I groups from Colombia revealed by low-stringency single specific primer-PCR of the intergenic regions of spliced-leader genes.

Authors:  Ana María Mejía-Jaramillo; Sair Arboleda-Sánchez; Ingrid Bibiana Rodríguez; Carolina Cura; Alexander Salazar; Jesús Del Mazo; Omar Triana-Chávez; Alejandro Gabriel Schijman
Journal:  Parasitol Res       Date:  2008-10-11       Impact factor: 2.289

4.  Treatment with benznidazole during the chronic phase of experimental Chagas' disease decreases cardiac alterations.

Authors:  Simone Garcia; Carolina O Ramos; Juliana F V Senra; Fabio Vilas-Boas; Maurício M Rodrigues; Antonio C Campos-de-Carvalho; Ricardo Ribeiro-Dos-Santos; Milena B P Soares
Journal:  Antimicrob Agents Chemother       Date:  2005-04       Impact factor: 5.191

5.  Activity of the new triazole derivative albaconazole against Trypanosoma (Schizotrypanum) cruzi in dog hosts.

Authors:  Paulo Marcos da Matta Guedes; Julio A Urbina; Marta de Lana; Luis C C Afonso; Vanja M Veloso; Washington L Tafuri; George L L Machado-Coelho; Egler Chiari; Maria Terezinha Bahia
Journal:  Antimicrob Agents Chemother       Date:  2004-11       Impact factor: 5.191

6.  Influence of the long-term Trypanosoma cruzi infection in vertebrate host on the genetic and biological diversity of the parasite.

Authors:  V M Veloso; A J Romanha; M Lana; S M F Murta; C M Carneiro; C F Alves; E C Borges; W L Tafuri; G L L Machado-Coelho; E Chiari; M T Bahia
Journal:  Parasitol Res       Date:  2005-06-07       Impact factor: 2.289

7.  Benznidazole therapy during acute phase of Chagas disease reduces parasite load but does not prevent chronic cardiac lesions.

Authors:  Ivo Santana Caldas; André Talvani; Sérgio Caldas; Cláudia Martins Carneiro; Marta de Lana; Paulo Marcos da Matta Guedes; Maria Terezinha Bahia
Journal:  Parasitol Res       Date:  2008-05-04       Impact factor: 2.289

8.  Sexual reproduction in a natural Trypanosoma cruzi population.

Authors:  Alexander S F Berry; Renzo Salazar-Sánchez; Ricardo Castillo-Neyra; Katty Borrini-Mayorí; Claudia Chipana-Ramos; Melina Vargas-Maquera; Jenny Ancca-Juarez; César Náquira-Velarde; Michael Z Levy; Dustin Brisson
Journal:  PLoS Negl Trop Dis       Date:  2019-05-20

9.  Nitroheterocyclic compounds are more efficacious than CYP51 inhibitors against Trypanosoma cruzi: implications for Chagas disease drug discovery and development.

Authors:  Carolina B Moraes; Miriam A Giardini; Hwayoung Kim; Caio H Franco; Adalberto M Araujo-Junior; Sergio Schenkman; Eric Chatelain; Lucio H Freitas-Junior
Journal:  Sci Rep       Date:  2014-04-16       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.